In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Ascent Pediatrics acetaminophen controlled-release beads NDA expected by end of 1997.

This article was originally published in The Tan Sheet

Executive Summary

ASCENT PEDIATRICS ACETAMINOPHEN CONTROLLED-RELEASE BEADS NDA FILING expected by the end of 1997 pending analysis of Phase III trial results, the company states in an April 25 initial public offering prospectus. Under development as an OTC treatment for pain and fever in children, Pediatemp beads would compete against marketed pediatric medications in liquid or chewable tablet forms, the company reports. As designed, the controlled-release product would enable eight-hour dosing, "rather than the four hours required for currently available products," Ascent states.





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts